Minutes instead of weeks, hundreds instead of thousands
In laboratories where time is measured in lives, a team at the University of Edinburgh has found a way to read the molecular story of a lung tumor not in weeks, but in minutes. Using light itself as a diagnostic instrument, their FLIM technology paired with artificial intelligence can identify the genetic mutations that determine whether a cancer will yield to targeted treatment — at a fraction of the current cost. In a disease that claims more lives than any other cancer worldwide, the distance between the right drug and the wrong one is the distance between hope and decline, and this method may help close it.
- Lung cancer patients are waiting weeks for genetic test results that determine their treatment, while their tumors continue to grow unchecked.
- Overstretched diagnostic labs are consuming scarce biopsy tissue and laboratory resources on slow, expensive sequencing processes that many healthcare systems can barely afford.
- Edinburgh researchers have turned to light rather than chemistry — their FLIM microscopy reads the natural fluorescence of tissue samples, letting AI predict critical EGFR mutations without destroying the sample or breaking the bank.
- In trials, the technique achieved high accuracy at a cost of hundreds of pounds rather than thousands, compressing a weeks-long process into minutes.
- The team is now pursuing clinical validation in real hospital settings and testing whether the platform can be extended to other mutations and cancer types.
- For hospitals in resource-limited regions where molecular testing barely exists, this tool could mean the difference between offering personalized cancer care and offering none at all.
A research team at the University of Edinburgh has developed a technique that could identify which lung cancer patients will respond to targeted drugs in minutes, at a cost of hundreds of pounds rather than thousands — a shift with profound implications for one of medicine's most urgent diagnostic challenges.
Today, when a biopsy arrives at the lab, pathologists must run expensive genetic sequencing to detect mutations in a gene called EGFR, which determines whether certain tumours will respond to specific drugs. The process is slow, consumes precious tissue, and in health systems without advanced molecular testing infrastructure, the wait can stretch for weeks while the cancer continues to progress.
The new approach uses fluorescence lifetime imaging microscopy — FLIM — which shines light on a tissue sample and captures the natural signals that bounce back. An AI then analyses those light patterns to predict not only whether EGFR mutations are present, but which type, since different mutations respond to different drugs. The technique achieved very high accuracy in the study, and crucially, it leaves the tissue intact.
Dr. Qiang Wang, who co-led the research, framed the stakes plainly: for hospitals in regions where molecular testing is scarce, this is not merely a financial question but a question of whether personalised treatment is possible at all. His co-lead, Professor Ahsan Akram, described the ambition of a single, non-destructive scan that could tell a clinician whether cancer is present, what type it is, and whether it will respond to targeted therapy — all in one step.
The researchers are now moving toward clinical validation in real hospital workflows, while also exploring whether FLIM can detect other targetable mutations and be applied to additional cancer types. If those efforts succeed, what began as a specialised research tool could become a routine instrument available wherever a microscope and a computer exist.
A team of researchers at the University of Edinburgh has developed a way to identify which lung cancer patients will respond to targeted drugs—in minutes, using a technique that costs hundreds of pounds instead of thousands. The breakthrough matters because lung cancer kills more people than any other cancer worldwide, and the difference between getting the right treatment and the wrong one can mean the difference between remission and decline.
Currently, when a patient's biopsy arrives at the lab, pathologists must run expensive genetic sequencing tests to look for specific mutations—particularly changes in a gene called EGFR—that determine whether a tumor will shrink in response to certain drugs. These tests are slow. They consume precious tissue from the biopsy. They tie up laboratory resources. In busy health systems, especially those without access to advanced molecular testing, the wait can stretch for weeks while the patient's cancer continues to grow.
The new method uses a technology called fluorescence lifetime imaging microscopy, or FLIM. Instead of grinding up tissue samples and sequencing their DNA, FLIM shines light on the biopsy and captures the natural fluorescence signals that bounce back. Artificial intelligence then analyzes those light patterns to predict whether the cancer carries EGFR mutations—and crucially, which type of EGFR mutation it is, since different mutations respond to different drugs. In the study, the technique achieved very high accuracy at making these predictions.
Dr. Qiang Wang, who co-led the research at the Institute for Regeneration and Repair, described the shift in stark terms: what now costs thousands of pounds and demands weeks of laboratory work could become a process taking minutes and costing hundreds. For hospitals in regions where molecular testing infrastructure is scarce or nonexistent, the difference is not merely financial. It is the difference between being able to offer personalized treatment and being unable to.
The pressure on diagnostic services is real and growing. Clinicians are seeing more patients with early-stage lung cancer—a consequence of better screening and awareness—which means more biopsies arriving at the lab. Each one requires analysis. Each one consumes tissue. Each one takes time. Dr. David Dorward, a thoracic pathologist at NHS Lothian, noted that technologies capable of extracting more information from smaller samples, quickly, will become essential as these diagnostic bottlenecks worsen.
Professor Ahsan Akram, the study's other co-lead, sketched a vision of what this could mean in practice: a single, non-destructive scan of a biopsy that tells a clinician whether a patient has cancer, what type it is, and whether it will respond to targeted therapy—all in one step, all quickly. That kind of efficiency could reshape how lung cancer diagnosis works, particularly in resource-limited settings where every tool must do multiple jobs.
The researchers are now moving toward clinical validation, the next phase where the technique must prove itself in real hospital workflows with real patients. They are also exploring whether FLIM can be extended to detect other targetable mutations and applied to other cancer types. If those efforts succeed, the platform could eventually become a standard part of how pathologists work—not a specialized test reserved for well-funded centers, but a routine tool available wherever a microscope and a computer exist.
Notable Quotes
This approach has the potential to take processes that currently cost thousands of pounds and require weeks of lab work and reduce them to something that takes minutes and costs hundreds.— Dr. Qiang Wang, Institute for Regeneration and Repair, University of Edinburgh
Technologies like this, which can deliver more information from smaller tissue samples at speed, will be essential for developing clinically effective diagnostic pathways.— Dr. David Dorward, consultant thoracic pathologist, NHS Lothian
The Hearth Conversation Another angle on the story
Why does it matter that this test takes minutes instead of weeks?
Because a patient with lung cancer is not waiting in a vacuum. The tumor is dividing. The clock is running. If you can tell a doctor in minutes whether a drug will work, they can start treatment immediately instead of waiting weeks for lab results. That acceleration compounds over months.
But the source says the method is less expensive. Is cost the real story here?
Cost matters enormously, but not for the reason you might think. It is not about saving money for its own sake. It is about access. A test that costs thousands of pounds can only exist in wealthy hospitals. A test that costs hundreds can exist everywhere. That is the story—democratizing diagnosis.
The technology uses light and AI instead of genetic sequencing. How does that actually work?
FLIM captures the natural fluorescence that tissue emits when light hits it. Different mutations create different light signatures. The AI learns to recognize those signatures. It is pattern recognition at the molecular level, but without destroying the tissue to read it.
What happens to the biopsy sample after this test?
That is the elegant part. The tissue is not consumed. It is not stained or processed or ground up. A pathologist could theoretically run other tests on the same sample afterward. You get more information from less material.
The researchers mention clinical validation next. What does that mean?
It means taking this lab success and testing it in actual hospitals with actual patients, where things are messier—different equipment, different technicians, different tissue quality. It has to work in the real world, not just in a controlled study.
If this works globally, what changes?
Lung cancer diagnosis becomes faster and cheaper everywhere, not just in wealthy countries. More patients get the right drug sooner. Pathology labs can handle more cases without hiring more staff. The bottleneck loosens.